NewCardio, Inc. (NWCI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NewCardio, Inc. (NWCI) trades at $0.00 with AI Score 58/100 (Grade B). NewCardio, Inc. focuses on developing and commercializing software platform technology solutions for non-invasive cardiovascular disease diagnosis and cardiac safety assessment. Market cap: $3,315, Sector: Healthcare.
Price live · AI analysis from Jun 1, 2026Analyst Coverage for NWCI: NWCI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NWCI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NWCI: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →NewCardio, Inc. (NWCI) Healthcare & Pipeline Overview
NewCardio, Inc., operating in the medical devices sector, specializes in cardiac diagnostic solutions, offering proprietary software for non-invasive cardiovascular disease monitoring and drug safety assessment. Their technology provides real-time, 3-D analysis of heart activity via standard ECG, positioning them in a niche market within the broader healthcare landscape.
What Is the Investment Thesis for NWCI?
NewCardio, Inc. presents a high-risk, high-reward investment profile within the medical devices sector. The company's focus on innovative cardiac diagnostic software, including QTinno and CardioBip, addresses a critical need for improved CVD monitoring and drug safety assessment. However, with a negative profit margin of -4466.2% and a small market capitalization, the company's financial stability is a significant concern. Growth catalysts include potential regulatory approvals for its products and strategic partnerships with pharmaceutical companies for cardiac safety assessments. The company's success hinges on its ability to commercialize its technology and secure funding to sustain operations.
Based on FMP financials and quantitative analysis
NWCI Key Highlights
- Market Cap of 3K indicates a micro-cap company with limited financial resources.
- Profit Margin of -4466.2% highlights significant losses and operational inefficiencies.
- Gross Margin of 40.8% suggests potential profitability if operating expenses are managed effectively.
- Beta of -120.60 indicates an inverse correlation with the market, which is unusual and may reflect company-specific factors rather than market trends.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth, typical for early-stage companies.
Who Are NWCI's Competitors?
NWCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| AXGN AxoGen, Inc. | $45.08 | -1.77% | $2.40B | 58 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| CYBQY CYBERDYNE Inc. | $2.16 | +45.06% | $385.21M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NWCI's Key Strengths?
- Proprietary software platform for cardiac diagnostics.
- Focus on non-invasive and real-time analysis.
- Potential for automated solutions to improve efficiency.
- Experienced management team in cardiac technology.
What Are NWCI's Weaknesses?
- Limited financial resources and negative profit margin.
- Small market capitalization and low trading volume.
- Dependence on regulatory approvals for product commercialization.
- Limited brand recognition and market presence.
What Could Drive NWCI Stock Higher?
- Potential regulatory approvals for QTinno and CardioBip.
- Strategic partnerships with pharmaceutical companies for cardiac safety assessments.
- Commercialization of my3KG software application.
- Expansion into remote patient monitoring market.
- International expansion into emerging markets.
What Are the Key Risks for NWCI?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Limited financial resources and negative profit margin.
- Competition from established medical device manufacturers.
- Technological obsolescence and rapid innovation.
- Regulatory hurdles and compliance requirements.
- Economic downturn and reduced healthcare spending.
What Are the Growth Opportunities for NWCI?
- Expansion of QTinno in Pharmaceutical Cardiac Safety: NewCardio has the opportunity to expand the adoption of its QTinno automated cardiac safety solution within the pharmaceutical industry. The market for cardiac safety assessment is driven by regulatory requirements for drug development, with pharmaceutical companies needing accurate and efficient methods for evaluating cardiac risks. QTinno's automated algorithms could offer a significant advantage over manual methods, potentially capturing a substantial share of this market. Timeline: Ongoing.
- Commercialization of CardioBip for Remote Patient Monitoring: The CardioBip mobile ECG transtelephonic system offers a growth opportunity in the remote patient monitoring market. As healthcare providers increasingly adopt telehealth solutions, the demand for remote cardiac monitoring devices is expected to grow. CardioBip's ability to transmit ECG data via mobile devices could make it a noteworthy option for patients and healthcare providers. Timeline: Ongoing.
- Development and Launch of my3KG Software Application: The development and launch of the my3KG software application presents a growth opportunity in the advanced cardiac analysis market. By providing a method to assess cardiac electrical activity in time and space, my3KG could offer valuable insights for diagnosing and managing complex cardiac conditions. Successful commercialization of my3KG could establish NewCardio as a leader in innovative cardiac diagnostic solutions. Timeline: Upcoming.
- Strategic Partnerships with Healthcare Providers: NewCardio can pursue strategic partnerships with hospitals, clinics, and other healthcare providers to integrate its technology into their cardiac care pathways. These partnerships could provide access to a larger patient base and facilitate the adoption of NewCardio's products. By collaborating with established healthcare providers, NewCardio can accelerate its market penetration and build credibility. Timeline: Ongoing.
- International Expansion into Emerging Markets: NewCardio has the opportunity to expand its operations into emerging markets, where the demand for affordable and accessible cardiac diagnostic solutions is growing. By adapting its products to meet the specific needs of these markets, NewCardio can tap into new revenue streams and diversify its geographic footprint. Successful international expansion could significantly increase the company's long-term growth potential. Timeline: Potential.
What Opportunities Does NWCI Have?
- Expansion into remote patient monitoring market.
- Strategic partnerships with pharmaceutical companies.
- International expansion into emerging markets.
- Development of new software applications for cardiac analysis.
What Threats Does NWCI Face?
- Competition from established medical device manufacturers.
- Technological obsolescence and rapid innovation.
- Regulatory hurdles and compliance requirements.
- Economic downturn and reduced healthcare spending.
What Are NWCI's Competitive Advantages?
- Proprietary software platform technology.
- Specialized expertise in cardiac diagnostics.
- Potential for regulatory approvals and patents.
- First-mover advantage in niche market segments.
What Does NWCI Do?
Founded in 2004 and based in Branchburg, New Jersey, NewCardio, Inc. is a cardiac diagnostic and services company focused on the research, development, and commercialization of proprietary software platform technology solutions. These solutions are designed for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's core technology platform enables real-time and 3-D analysis of the heart's electrical activity, utilizing standard 12-lead electrocardiogram (ECG) electrodes applied to the body surface. NewCardio's developing products include QTinno, an automated cardiac safety solution intended to replace manual or semi-automated methodologies with algorithms that automatically measure, analyze, and report on ECG data. Another key product is CardioBip, a mobile ECG transtelephonic system that comprises a mobile ECG recording and transmitting device, coupled with web-enabled software for data reception, processing, and analysis. The company is also developing my3KG, a software application designed to assess cardiac electrical activity in both time and space. NewCardio aims to improve the efficiency and accuracy of cardiac diagnostics through innovative software solutions.
What Products and Services Does NWCI Offer?
- Develop proprietary software platform technology solutions for cardiac diagnostics.
- Offer non-invasive diagnosis and monitoring of cardiovascular disease (CVD).
- Provide cardiac safety assessment of drugs under development.
- Offer real-time and 3-D analysis of the heart's electrical activity.
- Develop QTinno, an automated cardiac safety solution.
- Develop CardioBip, a mobile ECG transtelephonic system.
- Develop my3KG, a software application to assess cardiac electrical activity in time and space.
How Does NWCI Make Money?
- Develop and sell cardiac diagnostic software solutions.
- Generate revenue through licensing agreements with pharmaceutical companies.
- Offer cardiac monitoring services to healthcare providers.
- Potentially generate revenue through subscription-based access to its software platforms.
What Industry Does NWCI Operate In?
NewCardio, Inc. operates within the medical devices industry, a sector characterized by rapid technological advancements and stringent regulatory requirements. The market for cardiac diagnostic devices is driven by the increasing prevalence of cardiovascular diseases and the growing demand for non-invasive monitoring solutions. Competition includes established medical device manufacturers and smaller, specialized technology companies. NewCardio's focus on software-based solutions and real-time analysis positions it within a niche segment of the market, potentially offering a competitive advantage if its technology proves superior and gains regulatory approval.
Who Are NWCI's Key Customers?
- Pharmaceutical companies requiring cardiac safety assessments.
- Hospitals and clinics providing cardiac care.
- Cardiologists and other healthcare professionals.
- Patients requiring remote cardiac monitoring.
Net buyingInsider Activity
The most recent 11 insider filings for NewCardio, Inc. break down as 0 sales and 11 purchases. On net that is roughly 401K shares acquired (about $820K) — insiders putting money in tends to read as conviction.
NWCI Valuation & Market Position
With a 3K market cap, NewCardio, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NWCI's quantitative score of 58/100 is below the peer average of 69/100.
ROE 496%Key Financial Metrics
Return on equity for NewCardio, Inc. stands at 496.3%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.72 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
NewCardio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
NewCardio, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Branchburg, US. The company is led by CEO Jess Emery Jones. NWCI has traded publicly since 2008.
NWCI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting that executives believe in a positive turnaround.
- Community sentiment has shifted positively with discussions highlighting potential breakthroughs in cardiac monitoring technology.
- There’s growing interest in the healthcare sector, particularly in innovative solutions like NewCardio's offerings, attracting more attention from investors.
- Market perception is buoyed by recent partnerships that could enhance product visibility and expand market reach.
Bear Case
- Some analysts express concerns about the competitive landscape, noting that established players may overshadow NewCardio's innovations.
- Social sentiment has shown skepticism regarding the company's ability to execute on its growth strategies effectively, raising doubts among investors.
- Recent financial reports indicate ongoing challenges in scaling operations, which could hinder long-term growth potential.
- Bearish community discussions emphasize the need for clearer communication from the management about future plans and product development timelines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NWCI Latest News
No recent news available for NWCI.
NWCI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NWCI.
Price Targets
Wall Street price target analysis for NWCI.
NWCI MoonshotScore
What does this score mean?
The MoonshotScore rates NWCI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jess Emery Jones
CEO
Jess Emery Jones serves as the CEO of NewCardio, Inc. His background includes managing teams and overseeing the operations of the company. While specific details on his prior experience and education are not provided, his leadership is critical to guiding NewCardio's strategic direction and product development efforts. His expertise is essential for navigating the complexities of the medical device industry and securing funding for the company's growth initiatives.
Track Record: Under Jess Emery Jones' leadership, NewCardio, Inc. has focused on the development and commercialization of its proprietary software platform technology. Key milestones include the development of QTinno, CardioBip, and my3KG. His leadership is crucial for navigating the challenges of a micro-cap company with limited resources and a negative profit margin.
NWCI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NewCardio, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, financial distress, or regulatory issues. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in NWCI.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of readily available financial information makes it difficult to assess the company's true financial condition.
- Low Liquidity: The low trading volume and wide bid-ask spreads can make it challenging to buy or sell shares.
- Regulatory Scrutiny: OTC Other companies are subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- Going Concern Risk: The company's negative profit margin and limited financial resources raise concerns about its ability to continue operating.
- Dilution Risk: The company may need to issue additional shares to raise capital, which could dilute existing shareholders' ownership.
- Verify the company's legal standing and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's products and technology.
- Understand the company's competitive landscape.
- Determine the company's capital structure and debt obligations.
- Consult with a qualified financial advisor.
- Focus on cardiac diagnostic software development.
- Development of QTinno, CardioBip, and my3KG.
- CEO Jess Emery Jones is in place.
- Company has been in operation since 2004.
- Company has 10 employees.
NewCardio, Inc. Healthcare Stock: Key Questions Answered
What does NewCardio, Inc. do?
NewCardio, Inc. is a cardiac diagnostic and services company that develops and commercializes proprietary software platform technology solutions. These solutions are designed for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity, utilizing standard 12-lead electrocardiogram (ECG) electrodes. Their key products under development include QTinno, CardioBip, and my3KG.
What do analysts say about NWCI stock?
As of 2026-06-01, there is no available analyst coverage or consensus on NewCardio, Inc. (NWCI) stock, likely due to its OTC listing and small market capitalization. Key valuation metrics such as price-to-earnings ratio and price-to-sales ratio are not meaningful given the company's negative profit margin. Growth considerations would depend on the successful commercialization of its products and the ability to secure funding. Investors should conduct their own thorough research and due diligence before considering an investment in NWCI.
What are the main risks for NWCI?
The main risks for NewCardio, Inc. include its limited financial resources, negative profit margin, and dependence on regulatory approvals for product commercialization. Competition from established medical device manufacturers and the risk of technological obsolescence also pose significant challenges. As an OTC-listed company, NWCI faces additional risks related to low liquidity, limited financial disclosure, and potential regulatory scrutiny. Investors should carefully consider these risks before investing in NWCI.
What are the key factors to evaluate for NWCI?
NewCardio, Inc. (NWCI) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does NWCI data refresh on this page?
NWCI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NWCI's recent stock price performance?
NewCardio, Inc. (NWCI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary software platform for cardiac diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NWCI overvalued or undervalued right now?
Valuing NewCardio, Inc. (NWCI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NWCI?
Before investing in NewCardio, Inc. (NWCI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC market investments carry significant risks.
- Analyst coverage is non-existent.